The NCT/UCC Dresden

At the National Center for Tumor Diseases (NCT) patients and scientists enter through the same door. This is more than just a symbol: NCT/UCC Dresden has made it its duty to connect research and patient care as closely as possible. That is why cancer patients in Dresden are treated based on the latest research results, which - in this form - is outstanding throughout Europe.

The supporting institutions of NCT/UCC Dresden are the German Cancer Research Center (DKFZ) Heidelberg, the Carl Gustav Carus Faculty of Medicine at TU Dresden, the University Hospital Carl Gustav Carus Dresden and the Helmholtz-Zentrum Dresden-Rossendorf (HZDR).

The new NCT/UCC building hosts the operating room of the future, laboratories, areas for clinical trials as well as rooms for medical treatment and radiotherapy.


There is no such thing as one disease named cancer. Instead it is a group of diseases, which originate from genetic changes - precisely mutations - but can develop very differently. To this day around 250 types of cancer are known. The biology of tumors differ in each and every patient.

Scientists and physicians at NCT therefore aim for a personalized cancer Treatment. Through various tests they determine the individual characteristics of a tumor, to be able to offer their patients a tailor-made therapy. To achieve that goal we work with the latest state-of-the-art techniques at the NCT sites.

NCT/UCC Dresden is based on 15 years of expertise in cancer research. It is built upon the structures of the University Cancer Center Dresden (UCC), which was founded as one of the first comprehensive cancer Centers in Germany. In 2007 UCC was honored with the title "Oncological Center of Excellence" by the German Cancer Aid (DKH). This award was renewed with every assessment ever since.

Furthermore NCT/UCC Dresden benefits from Centers of Excellence like the OncoRay - National Center for Radiation Research in Oncology and the partner site Dresden of the German Cancer Consortium (DKTK).

More than 500 physicians, scientists and other employees of the University Hospital and its partners currently work on treating cancer patients at the highest standards and improving therapy through their research activities. At the Helmholtz-Zentrum Dresden-Rossendorf another 150 scientists and employees aim for that goal. With the establishment of NCT/UCC Dresden about 200 new positions will be created.

In Dresden, the second NCT site in Germany after Heidelberg is being established since 2015. Prof. Dr. Stefanie Speidel and Prof. Dr. Hanno Glimm hold the first two professorships that are funded by NCT/UCC Dresden. Prof. Speidel is doing innovative research in translational surgical oncology, while Prof. Glimm is a leading clinician scientist in the field of translational medical oncology. Soon, the professor for "Translational Imaging in Oncology" will be announced. Two more professorships are going to follow shortly.

Apart from that, selected tumor-specific research areas will be extended. NCT/UCC Dresden is also creating the ideal infrastructure for its three core units Molecular Tumor Diagnostics, Immune Monitoring and Data and Trial Management.

The new NCT/UCC building on the grounds of the University Hospital Carl Gustav Carus Dresden provides researchers with a unique connection of innovative surgery methods, imaging techniques and radiation therapy. Furthermore it houses facilities for patient studies about innovative research approaches in medical oncology and molecular tumor diagnostics and some specialized research laboratories.